DRAFT legislation currently before the Indian parliament to allow dual citizenship has been widely applauded by the biggest diaspora in the world as it is likely to provide significant benefits for its members.
The concept of ‘global Indians’ has grown through the phenomenal success of the Indian diaspora across the international business, media, and cultural communities.
Dominic Volek, Head of Southeast Asia at London based investment migration firm, Henley & Partners said: “There has been a noteworthy spike in interest recently among high-net-worth Indian nationals regarding residence-by-investment options.
“We have seen a significant increase year on year of Indian citizens looking to manage their global mobility challenges and invest in residence-based programs. Amending the constitution to allow dual citizenship would allow Indians to take advantage of belonging to multiple jurisdictions, providing them with greater freedom, opportunity, and ease of international travel.
“Moreover, holding two passports makes it easier to retain community ties within a country of origin while also being an active civic participant in a new home country.”
India’s opposition MP Shashi Tharoor introduced a bill a few weeks ago to amend the Indian Constitution, which currently requires that Indian nationals give up their passports once they have obtained citizenship of another country.
Tharoor argues that many Indians have migrated abroad for new opportunities- seeking access to a higher quality of life, better education, high-paying jobs in multilateral organizations, or merely for mobility and travel freedom and taking a foreign passport for convenience does not make them any less Indian.
According to the UN World Migration Report 2018, over 15.6 million Indians are living in other countries, making it the largest mass dispersion of a population globally.
The 2019 Wealth-X report states that India is one of the top 10 fastest-growing high-net-worth countries, alongside other Asian countries such as Bangladesh, China, the Philippines, and Vietnam.
Statistics show that there has been significant interest from Indian clients, centred on Greek, Maltese, and Portuguese residence programs in Europe, where minimum investments start at €250,000, €330,000, and €250,000, respectively.
Outside the EU and Europe’s Schengen Area, the Thailand Elite Residence Program, the UK Investor Immigration Program, the US EB-5 Immigrant Investor Program, and various investor visas in Australia including the Significant Investor Visa (SIV) stream are also very popular options.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.